ArticleCase reports in oncology
Divergent Responses to Enfortumab Vedotin and Pembrolizumab in Concurrent Urothelial and Renal Cell Carcinoma: Case Report and Literature Review.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized the treatment of metastatic urothelial carcinoma (UC) and renal cell carcinoma (RCC). However, these cancers may exhibit divergent responses to the same immunotherapy. Case Presentation: Here, we report a case of a patient with concurrent stage 4 UC and resected stage III clear cell RCC (ccRCC) who experienced complete remission of UC following treatment with enfortumab vedotin (EV) and pembrolizumab but developed hyperprogression of metastatic RCC. The decision was made to discontinue ICIs and initiate a combination therapy of lenvatinib (VEGF receptor inhibitor) and everolimus (mTOR inhibitor). The patient exhibited a complete radiographic response to this combination therapy, with no significant side effects, and has remained well 18 months after the onset of hyperprogression in ccRCC. Conclusion: We highlight the role of distinct immune microenvironments in mediating differential responses to immunotherapy, in patients with coexisting UC and ccRCC. We underscore the importance of personalized treatment strategies in patients with dual malignancies, particularly when divergent responses to immunotherapy are observed, offering durable responses while avoiding the risks associated with continued immune checkpoint inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.